NanoSanguis

NanoSanguis is a Polish biotechnology company focused on developing solutions for transplantation and transfusion medicine. The company originated from a team of scientists at the Warsaw University of Technology who were working on oxygen therapy technology. It was officially founded in December 2015 by Tomasz Ciach and Agata Stefanek, in collaboration with venture capital funds Start Venture Poland and Giza Polish Ventures, to commercialize a safe and effective red blood cell substitute.

The company is addressing two critical challenges in healthcare: the shortage of organs for transplantation and the growing deficit of donor blood. Hundreds of thousands of patients are on waiting lists for kidney transplants, and a significant number are removed annually due to health deterioration or death. Simultaneously, the demand for blood is increasing, but its short 40-day shelf life leads to considerable waste.

NanoSanguis has developed two primary technologies. The first is a red blood cell substitute, an artificial oxygen carrier that can be used in transfusions. This synthetic fluid is designed to transport oxygen and carbon dioxide, mimicking the function of natural blood. Its potential benefits include a longer shelf life of at least a year, universal compatibility with all blood groups, and freedom from pathogens, which reduces the risk of transfusion-transmitted infections. The second core technology is the NanOX system, which combines a perfusion fluid with a medical device for preserving organs, particularly kidneys, for transplantation. This system uses perfluorocarbon nanoparticles to supply oxygen and support the metabolism of organs, which may allow for their regeneration and increases the viability of organs that have experienced prolonged ischemia.

The company's business model appears focused on the research and development of these technologies with the goal of selling the projects at the pre-clinical research stage or partnering for further development and commercialization. The target clients for these technologies are medical institutions, such as hospitals and transplant centers, that perform surgeries, transfusions, and organ transplants. NanoSanguis operates in the biotechnology and medical device markets, specifically within the fields of transfusion medicine and organ preservation.

Keywords: artificial blood, red blood cell substitute, organ preservation, transplantation medicine, transfusion medicine, NanOX system, perfluorocarbon nanoparticles, oxygen carrier, kidney perfusion, biotechnology, medical device, organ shortage, blood substitute, ischemia, nanotechnology, Warsaw University of Technology, Tomasz Ciach, Agata Stefanek, Giza Polish Ventures, medical research